Caroline Even
About
Caroline Even is a scholar working on Oncology, Otorhinolaryngology and Surgery.
According to data from OpenAlex, Caroline Even has authored 142 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 75 papers in Otorhinolaryngology and 59 papers in Surgery. Recurrent topics in Caroline Even's work include Head and Neck Cancer Studies (75 papers), Cancer Immunotherapy and Biomarkers (51 papers) and Lung Cancer Treatments and Mutations (25 papers). Caroline Even is often cited by papers focused on Head and Neck Cancer Studies (75 papers), Cancer Immunotherapy and Biomarkers (51 papers) and Lung Cancer Treatments and Mutations (25 papers). Caroline Even collaborates with scholars based in France, United States and United Kingdom. Caroline Even's co-authors include Christophe Le Tourneau, J. Guigay, Jérôme Fayette, Esma Saâda-Bouzid, Frédéric Peyrade, Virginia Palomar Coloma, Delphine Loirat, Xavier Paolettí, Vincent Servois and Andy Karabajakian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Caroline Even
138 papers receiving 2.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Caroline Even France | 22 | 1.8k | 853 | 812 | 692 | 411 | 142 | 2.5k | ||
| Glenn J. Hanna United States | 26 | 1.4k 0.8× | 756 0.9× | 582 0.7× | 522 0.8× | 309 0.8× | 149 | 2.6k | ||
| Ammar Sukari United States | 24 | 1.5k 0.9× | 372 0.4× | 635 0.8× | 311 0.4× | 381 0.9× | 118 | 2.3k | ||
| Deborah Jean Lee Wong United States | 14 | 887 0.5× | 328 0.4× | 396 0.5× | 321 0.5× | 408 1.0× | 53 | 1.6k | ||
| Sing Fai Leung Hong Kong | 21 | 1.1k 0.6× | 1.6k 1.9× | 712 0.9× | 1.1k 1.6× | 69 0.2× | 41 | 2.4k | ||
| Shubhada Kane India | 26 | 1.1k 0.6× | 1.1k 1.2× | 390 0.5× | 1.1k 1.5× | 57 0.1× | 104 | 2.6k | ||
| Sandra Schmitz Belgium | 21 | 614 0.4× | 483 0.6× | 385 0.5× | 504 0.7× | 91 0.2× | 67 | 1.4k | ||
| Jean‐Pascal Machiels Belgium | 23 | 808 0.5× | 251 0.3× | 290 0.4× | 286 0.4× | 170 0.4× | 58 | 1.6k | ||
| Harlan Pinto United States | 14 | 1.0k 0.6× | 2.2k 2.6× | 685 0.8× | 1.3k 1.9× | 80 0.2× | 28 | 2.9k | ||
| Carmen Gomez‐Fernandez United States | 25 | 1.1k 0.6× | 160 0.2× | 476 0.6× | 627 0.9× | 111 0.3× | 88 | 2.3k | ||
| Markus Hecht Germany | 23 | 891 0.5× | 168 0.2× | 289 0.4× | 240 0.3× | 336 0.8× | 102 | 1.4k |
Countries citing papers authored by Caroline Even
Since
Specialization
Citations
This map shows the geographic impact of Caroline Even's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Even with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Even more than expected).
Fields of papers citing papers by Caroline Even
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Caroline Even. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Even. The network helps show where Caroline Even may publish in the future.
Co-authorship network of co-authors of Caroline Even
This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Even. A scholar is included among the top collaborators of Caroline Even based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Even. Caroline Even is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fayette, Jérôme, Caroline Even, Laurence Digue, et al.. (2023). NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). SHILAP Revista de lepidopterología. 2(1). e000065–e000065.
2.
Chabrillac, É., Caroline Even, Valérie Costes‐Martineau, et al.. (2023). Cancers rares de la tête et du cou sous l’égide du REFCOR, partie 1. Bulletin du Cancer. 110(6). 692–699.
3.
Chabrillac, É., Caroline Even, Valérie Costes‐Martineau, et al.. (2023). Cancers rares de la tête et du cou sous l’égide du REFCOR, partie 2. Bulletin du Cancer. 110(6). 700–706.
4.
Laparra, Ariane, François‐Xavier Danlos, Antoine Hollebecque, et al.. (2023). Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. European Journal of Cancer. 193. 113313–113313.
5.
Digue, Laurence, S. Vergèz, Juliette Thariat, et al.. (2023). Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method. European Annals of Otorhinolaryngology Head and Neck Diseases. 141(5). 280–285.
6.
Wildsmith, Sophie, Jiabu Ye, Giovanni Melillo, et al.. (2022). Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. Cancer Research Communications. 2(1). 39–48.
7.
Durand, Sylvère, Matthieu Texier, Amaury Daste, et al.. (2022). Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. OncoImmunology. 12(1). 2150472–2150472.
8.
Saleh, Khalil, Anne Aupérin, Nicolas Martin, et al.. (2021). Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer. 157. 190–197.
9.
Ho, Alan L., Daniel W. Bowles, Caroline Even, et al.. (2021). 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort. Annals of Oncology. 32. S803–S804.
10.
Thariat, Juliette, Benjamin Vérillaud, S. Vergèz, et al.. (2020). Diagnostic, pronostic et traitement des carcinomes nasosinusiens (hors mélanomes, sarcomes et lymphomes). Bulletin du Cancer. 107(5). 601–611.
11.
Ferrarotto, Renata, Lori J. Wirth, Jameel Muzaffar, et al.. (2020). 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Annals of Oncology. 31. S663–S663.
12.
Deutsch, Éric, Benjamin Besse, Jérôme Le Pavec, et al.. (2020). Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology. 154. 125–127.
13.
Ferris, Robert L., Lisa Licitra, Jérôme Fayette, et al.. (2019). Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clinical Cancer Research. 25(17). 5221–5230.
14.
Even, Caroline, Ulrik Lassen, Jaime R. Merchan, et al.. (2019). Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Investigational New Drugs. 38(2). 402–409.
15.
Saâda-Bouzid, Esma, Andy Karabajakian, Virginia Palomar Coloma, et al.. (2017). Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology. 28(7). 1605–1611.
16.
Guigay, J., François Bidault, Jérôme Fayette, et al.. (2016). Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR. Annals of Oncology. 27. vi340–vi340.
17.
Cesne, Axel Le, Isabelle Ray‐Coquard, Florence Duffaud, et al.. (2015). Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. European Journal of Cancer. 51(6). 742–750.
18.
Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93.
19.
Duffaud, Florence, Caroline Even, Isabelle Ray‐Coquard, et al.. (2012). Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. SHILAP Revista de lepidopterología. 2(1). 11–11.
20.
Rouge, T. De La Motte, Judith Michels, Caroline Even, et al.. (2009). Nouvelles molécules et thérapeutiques moléculaires ciblées dans les adénocarcinomes ovariens de stades avancés. Bulletin du Cancer. 96(12). 1215–1224.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Glenn J. Hanna Breakdown of academic impact, for papers by Ammar Sukari Breakdown of academic impact, for papers by Deborah Jean Lee Wong Breakdown of academic impact, for papers by Sing Fai Leung Breakdown of academic impact, for papers by Shubhada Kane Breakdown of academic impact, for papers by Sandra Schmitz Breakdown of academic impact, for papers by Jean‐Pascal Machiels Breakdown of academic impact, for papers by Harlan Pinto Breakdown of academic impact, for papers by Carmen Gomez‐Fernandez Breakdown of academic impact, for papers by Markus Hecht